Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant

This cohort study examines safety and antibody responses after 1 and 2 doses of BNT162b2 mRNA vaccine in recipients of allogeneic hematopoietic stem cell transplant (HSCT).

Detalles Bibliográficos
Autores principales: Le Bourgeois, Amandine, Coste-Burel, Marianne, Guillaume, Thierry, Peterlin, Pierre, Garnier, Alice, Béné, Marie C., Chevallier, Patrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441592/
https://www.ncbi.nlm.nih.gov/pubmed/34519770
http://dx.doi.org/10.1001/jamanetworkopen.2021.26344

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441592/
https://www.ncbi.nlm.nih.gov/pubmed/34519770
http://dx.doi.org/10.1001/jamanetworkopen.2021.26344

Ejemplares similares